Smith Smith MR MR Phase 2 study of the safety and antitumor activity of apalutamide (ARN-509), a potent androgen receptor antagonist, in the high-risk nonmetastatic castration-resistant prostate cancer cohort Phase 2 study of the safety and antitumor activity of apalutamide (ARN-509), a potent androgen receptor antagonist, in the high-risk nonmetastatic castration-resistant prostate cancer cohort Eur Urol Eur Urol 2016 2016 70 70 963 963 970 970 10.1016/j.eururo.2016.04.023 10.1016/j.eururo.2016.04.023 27160947 27160947. This evidence concerns the gene AR and prostate carcinoma.